Office-Based Treatment for BPH

A microwave thermotherapy system is designed for in-office use to treat benign prostate hyperplasia (BPH). The system, called CoreTherm, has been cleared by the US Food and Drug Administration (FDA).

Until recently, the most common method of treating BPH was a transurethral resection of the prostate (TURP), performed under anesthesia. In a randomized study conducted in Scandinavia and the United States, researchers found two significant differences between CoreTherm treatments and TURP with regard to important parameters such as prostate volume and detrusor pressure.

CoreTherm is the only office-based microwave system that enables the urologist to control the amount of prostate tissue treated, says the developer, ProstaLund Operations AB (Lund, Sweden). Patented technology built into the system allows the urologist to continuously measure the intraprostatic temperature during the procedure. This enables doctors to treat patients on an individualized basis.

"The ability to customize the treatment should allow urologists to achieve more consistent outcomes with an added margin for patient safety,” noted Dr. Stanley Swierzewski, of Hampden Urological Associates (Holyoke, MA, USA), who performed the first US treatments. ProstaLund has assigned distribution rights in North and South America to ACMI Corp. (Southborough, MA, USA).




Related Links:
ProstaLund